Q1 2026 · 13F-HR
CAXTON CORPholdings as filed
Filed 2026-05-14 · accession 0000919574-26-003017
$4.0M
Reported value
7
Positions
2026-03-31
Period end
The Brief · CAXTON CORP · Q1 2026
AI · grounded in 13F
CAXTON CORP closed its position in SYRE, reducing its exposure by $292,194. The fund also exited positions in BRD1EUR and CMPX, with losses of $210,058 and $158,386 respectively. To offset these exits, the fund established a new position in ALXO worth $41,996 and increased its holdings in GLD by 9.463%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 78463V107 | GLD | SPDR GOLD TR | $3.3M | 81.5% | 7,623 | Common | SOLE |
| 084670702 | BRK/B | BERKSHIRE HATHAWAY INC DEL | $348,341 | 8.66% | 727 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $162,012 | 4.03% | 18,773 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $80,032 | 1.99% | 13,943 | Common | SOLE |
| 98420X202 | XFOR | X4 PHARMACEUTICALS INC | $64,249 | 1.60% | 15,557 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $47,801 | 1.19% | 28,453 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $41,996 | 1.04% | 20,946 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.